Biogen Inc. (BIIB)
NASDAQ: BIIB · Real-Time Price · USD
183.34
-2.34 (-1.26%)
Oct 7, 2024, 4:00 PM EDT - Market closed
Biogen Revenue
Biogen had revenue of $2.46B in the quarter ending June 30, 2024, with 0.36% growth. This brings the company's revenue in the last twelve months to $9.67B, down -3.00% year-over-year. In the year 2023, Biogen had annual revenue of $9.84B, down -3.32%.
Revenue (ttm)
$9.67B
Revenue Growth
-3.00%
P/S Ratio
2.75
Revenue / Employee
$1,277,675
Employees
7,570
Market Cap
26.71B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 9.84B | -337.80M | -3.32% |
| Dec 31, 2022 | 10.17B | -808.30M | -7.36% |
| Dec 31, 2021 | 10.98B | -2.46B | -18.32% |
| Dec 31, 2020 | 13.44B | -933.30M | -6.49% |
| Dec 31, 2019 | 14.38B | 925.00M | 6.88% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cardinal Health | 226.83B |
| Humana | 112.04B |
| Koninklijke Philips | 19.43B |
| ICON Public Limited Company | 8.33B |
| STERIS | 5.23B |
| Moderna | 5.05B |
| Illumina | 4.43B |
| DexCom | 3.93B |
BIIB News
- 1 day ago - Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma - Seeking Alpha
- 13 days ago - Biogen and Belgian partner UCB announce positive data from late-stage trial of lupus treatment - Market Watch
- 13 days ago - Biogen-UCB's lupus drug meets main goal of late-stage trial - Reuters
- 13 days ago - UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024 - GlobeNewsWire
- 17 days ago - Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Aflibercept Biosimilar, OPUVIZ™ - GlobeNewsWire
- 19 days ago - Biogen Inc. (BIIB) Cantor Fitzgerald Global Healthcare Conference (Transcript) - Seeking Alpha
- 25 days ago - US Rheumatologists Believe Biogen's Litifilimab Is the Leading SLE Pipeline Asset Poised to Offer Improvement Over Benlysta and Saphnelo Based on Clinical Trial Data - GlobeNewsWire
- 25 days ago - Healthcare Stocks Have Popped. Consider These 2 That Haven't. - Barrons